טוען...
Combination of proteasome and HDAC inhibitor enhances HPV16 E7-specific CD8(+) T cell immune response and antitumor effects in a preclinical cervical cancer model
BACKGROUND: Bortezomib, a proteasome inhibitor and suberoylanilide hydroxamic acid (SAHA, also known as Vorinostat), a histone deacetylase inhibitor, have been recognized as potent chemotherapeutic drugs. Bortezomib and SAHA are FDA-approved for the treatment of cutaneous T cell lymphoma and multipl...
שמור ב:
| הוצא לאור ב: | J Biomed Sci |
|---|---|
| Main Authors: | , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
BioMed Central
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4298946/ https://ncbi.nlm.nih.gov/pubmed/25591912 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12929-014-0111-1 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|